Biotechnology

Filter

Current filters:

None

Popular Filters

1964 to 1988 of 2250 results

Celgene makes $15 million investment in Acetylon

10-02-2012

US biotech Celgene (Nasdaq: CELG) will invest a total of $15 million in Acetylon Pharmaceuticals via…

Acetylon PharmaceuticalsBiotechnologyCelgeneFinancial

Amgen fails to get FDA advisory backing for extended use of Xgeva

09-02-2012

The world’s largest independent biotech firm, Amgen (Nasdaq: AMGN), has failed to convince a Food…

AmgenBiotechnologyNorth AmericaOncologyPharmaceuticalRegulationXgeva

Positive Ph II results for Genzyme’s oral Gaucher drug

09-02-2012

French drug major Sanofi’s (Euronext: SAN) US subsidiary Genzyme yesterday revealed four-year follow-up…

BiotechnologyeliglustatGenzymePharmaceuticalRare diseasesResearchSanofi

Elan back in the black, boosted by Tysabri

09-02-2012

Ireland headquartered biotech company Elan Corp (LSE: ELN) has reported its fourth-quarter 2011 results…

BiotechnologyElanFinancialTysabri

Amylin 4th-qtr loss widens on charges

07-02-2012

US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN) reported that in loss for the fourth quarter of…

AmylinBiotechnologyBydureonByettaDiabetesFinancial

AusBiotech sets out stall on R&D tax incentive discussion paper

07-02-2012

Australian trade group AusBiotech has lodged a submission in response to the “Discussion Paper:…

Asia-PacificBiotechnologyFinancialResearch

Reinventing biopharma: Strategies for an evolving marketplace

07-02-2012

The biopharmaceutical industry today is facing a multifaceted “value challenge”. It is no longer…

BiotechnologyGlobalMarkets & MarketingPharmaceuticalPricingRegulation

Merck KGaA licenses pancreatic cancer drug from Threshold

06-02-2012

Merck Serono, a division of German pharma and chemical major Merck KGaA (MRK: DE) has signed a global…

BiotechnologyLicensingMerck KGaAMerck SeronoOncologyPharmaceuticalThreshold Pharmaceuticals

Sobi and Biogen Idec flesh out details of hemophilia programs

06-02-2012

Stockholm-based Swedish Orphan Biovitrum (STO: SOBI) and US biotech company Biogen Idec (Nasdaq: BIIB)…

Biogen IdecBiotechnologyCardio-vascularLicensingPharmaceuticalSwedish Orphan Biovitrum

Genfit’s GFT505 improves insulin sensitivity

05-02-2012

French biotech firm Genfit (Alternext: ALGFT) says that its leading drug candidate GFT505 in a Phase…

BiotechnologyDiabetesGenfitResearch

EMA planning fundamental change in pharmacovigilance rules

03-02-2012

The European Medicines Agency, together with the European Union member states and the European Commission,…

BiotechnologyEuropePharmaceuticalRegulation

2011 financial briefs for Alkermes, Allergan, Gilead and Vertex

03-02-2012

Among the plethora of financial results being reported by US biotech and pharmaceutical companies were…

AlkermesAllerganBiotechnologyFinancialGilead SciencesPharmaceuticalVertex

Biotech deal-making off to a strong start in 2012, says Burrill

02-02-2012

Swiss drug major Roche's hostile $5.7 billion bid for the tools and sequencing systems company Illumina…

BiotechnologyFinancialLicensingMergers & AcquisitionsNorth America

RegeneRx explores strategic options

02-02-2012

US biotech firm RegeneRx Biopharmaceuticals. (OTC Bulletin Board: RGRX) revealed yesterday that it has…

BiotechnologyCardio-vascularDermatologicalsLicensingNeurologicalOphthalmicsRegeneRx

Solid 2011 financials from Biogen Idec but forecast disappoints

01-02-2012

US biotech firm Biogen Idec (Nasdaq: BIIB) announced its full year and fourth quarter 2011 results which…

Biogen IdecBiotechnologyFinancial

Immuron joins academia for C. Difficile therapeutics

31-01-2012

Australian biotechnology firm Immuron (ASX: IMC) has entered into a collaboration agreement with Australia’s…

Antibiotics and Infectious diseasesAsia-PacificBiotechnologyImmuronResearch

New hope for amyloidosis patients facing organ transplants

31-01-2012

Amyloidosis patients are expected to see some significant breakthroughs in treatment over the next three…

BiotechnologyMarkets & MarketingPharmaceuticalRare diseasesResearch

Faster-than-expected FDA approval of Roche’s vismodegib

31-01-2012

There was good news for Swiss drug major Roche's (ROG: SIX)subsidiary Genentech yesterday, when it received…

BiotechnologyCurisErivedgeGenentechNorth AmericaOncologyPharmaceuticalRegulationRochevismodegib

Cell Therapeutics updates on Pixuvri

30-01-2012

Seattle, USA-based Cell Therapeutics (Nasdaq and MTA: CTIC) says that it has voluntarily withdrawn its…

BiotechnologyCell TherapeuticsNorth AmericaOncologyPixuvriRegulation

Irish pharma sees failures in ESRI report on use of pharmaceuticals

30-01-2012

A new report by Ireland’s Economic and Social Research Institute (ESRI) has recommended new ways…

BiotechnologyEuropePharmaceuticalPricingRegulation

Lower anemia drug sales hit Amgen profit

30-01-2012

Global independent biotech leader Amgen (Nasdaq: AMGN) reported fourth-quarter 2011 results with 3% growth…

AmgenBiotechnologyFinancial

GenVec extends research deal with Novartis

29-01-2012

US biopharma company GenVec (Nasdaq: GNVC) says that it has extended its research collaboration and license…

BiotechnologyGenVecNeurologicalNovartisPharmaceuticalResearch

Amgen to acquire US/German biotech firm

27-01-2012

Adding to the strong start this year for M&A activity in the Pharma/Biotech sector, USA-based Amgen (Nasdaq:…

AmgenBiotechnologyMergers & AcquisitionsMicrometOncology

1964 to 1988 of 2250 results

Back to top